Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: J Subst Abuse Treat. 2022 Apr 30;139:108785. doi: 10.1016/j.jsat.2022.108785

Table 1:

Demographic characteristics of included patients and naloxone prescription rates.

Naloxone Prescribed

Total Yes No p value1
n=1,342 n=580 (43.2%) n=762 (56.8%)

Age Group (years) 16-24 64 (4.8%) 31 (5.3%) 33 (4.3%) 0.01
25-34 384 (28.6%) 187 (32.2%) 197 (25.9%)
35-44 422 (31.4%) 181 (31.2%) 241 (31.6%)
45-54 224 (16.7%) 90 (15.5%) 134 (17.6%)
55-64 170 (12.7%) 71 (12.2%) 99 (13.0%)
65+ 78 (5.8%) 20 (3.4%) 58 (7.6%)

Gender Female 417 (31.1%) 164 (28.3%) 253 (33.2%) 0.06
Male 925 (68.9%) 416 (71.7%) 509 (66.8%)

Race/Ethnicity Hispanic/Latinx 175 (13.0%) 93 (16.0%) 82 (10.8%) 0.004
Non-Hispanic Black 108 (8.0%) 49 (8.4%) 59 (7.7%)
Non-Hispanic White 1,000 (74.5%) 403 (69.5%) 597 (78.3%)
Other2 32 (2.4%) 20 (3.4%) 12 (1.6%)
Unknown 27 (2.0%) 15 (2.6%) 12 (1.6%)

Primary Language English 1,293 (96.3%) 561 (96.7%) 732 (96.1%) 0.89
Non-English 32 (2.4%) 12 (2.1%) 20 (2.6%)
Unknown 17 (1.3%) 7 (1.2%) 10 (1.3%)
1

P-values calculated with Chi-square analysis. Bolded values indicate results statistically significant at the p<0.05 level.

2

The “Other” race/ethnicity category included Asian (n=10), American Indian or Alaska Native (n=1), two or more (n=13), and “other”, as recorded in our electronic health record (n=8).